---

Molecular Markers in Cervical Cancer Screening: A Detailed Overview

---

1. The Biological Rationale

• Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 926

---

2. Cervical Cytology (Papanicolaou Smear) - The Historical Foundation

---

3. Primary HPV Molecular Testing

3.1 FDA-Approved Assays

3.2 HPV DNA vs. HPV mRNA Testing

---

4. p16^INK4a and p16/Ki-67 Dual Stain - The Most Validated Biomarker

4.1 Mechanism

4.2 Clinical Performance (PALMS Study - Key Validation Data)

4.3 ASCCP 2024 Recommendations for p16/Ki-67 Dual Stain

---

5. HPV Extended Genotyping

• HPV 16 accounts for ~50-60% of all cervical cancers
• HPV 18 accounts for ~10-15%
• Together they represent the highest-risk genotypes

---

6. DNA Methylation Markers

6.1 Mechanism

6.2 Key Methylation Targets

6.3 Pooled Performance (Systematic Review, PMID 37533074, n = 23 studies)

---

7. Serum and Circulating Tumor Markers

7.1 Squamous Cell Carcinoma Antigen (SCC-Ag)

• A serine protease inhibitor overexpressed in squamous cell carcinoma of the cervix
• Not used for primary screening (low sensitivity for early disease)
• Established role in monitoring treatment response and recurrence surveillance
• Emerging data: optimal cutoffs in combination with HPV metrics, methylation markers, and ctDNA improve early recurrence detection and personalize follow-up (PMC12731993, 2025)

7.2 Circulating Tumor DNA (ctDNA) / HPV-ctDNA

• HPV circulating tumor DNA (HPV-ctDNA): fragments of HPV DNA shed from tumor cells into circulation
• Host-gene aberrations: copy number variations, somatic mutations in PI3K pathway, KRAS, TP53

7.3 Other Tumor Markers

---

8. Emerging and Investigational Markers

---

9. Current Screening Algorithms - How Markers Are Integrated

USPSTF 2024 Draft Recommendation (USA)

ASCCP Triage Algorithm (2024-2025)

Primary HPV Test
      |
      ├── HPV Negative → Routine screening interval (5 years if primary HPV)
      │
      └── HPV Positive
              |
              ├── HPV 16 or 18 → COLPOSCOPY (regardless of other results)
              │
              └── Other hrHPV
                      |
                      ├── Option A: Reflex Cytology
                      │     ├── NILM → 1-year retest
                      │     └── ASC-US+ → Colposcopy
                      │
                      ├── Option B: p16/Ki-67 Dual Stain
                      │     ├── DS+ → Colposcopy
                      │     └── DS- → 1-year HPV-based retest
                      │
                      └── Option C: Extended Genotyping (HPV 31/33/45/52/58)
                            ├── High-risk genotype → Colposcopy
                            └── Lower-risk genotype → Surveillance

Italian Multisocietal Guideline 2025 (GRADE-Based)

• Risk-based thresholds defined using CIN3+ as surrogate cancer risk marker
• Conditional recommendation (GRADE): Combination of morphological markers (cytology or p16/Ki-67) combined with extended HPV genotyping was the only strategy with a positive recommendation versus cytology alone
• Three-tier management: immediate colposcopy / 1-year retest / 3-year retest - driven by CIN3+ risk probability

---

10. Comparative Summary of Molecular Markers

---

11. Special Considerations

Self-Sampling (ASCCP April 2025)

• Self-collected vaginal samples for hrHPV testing formally endorsed in clinical settings
• Performance equivalent to clinician-collected for HPV DNA detection
• Greatly improves access; molecular markers (DS, methylation) compatible with self-collected LBC samples

Low-Resource Settings

• p16^INK4a single-stain IHC on conventional smears offers a cost-effective alternative to dual stain
• HPV DNA testing with visual triage (VIA + p16) being evaluated by WHO for low-income countries
• GeneXpert (point-of-care HPV testing) increasingly deployed

HPV-Independent Cervical Cancer

• Approximately 5% of cervical cancers are hrHPV-negative
• Driven by KRAS mutations, ERBB2 amplification, or chromosomal instability
• Standard HPV-based screening will miss these; no established molecular screening strategy yet
• Represents an important gap recognized in 2024-2025 literature

---

Key Takeaways

1. Primary hrHPV testing is now the preferred first-line molecular screening strategy for women aged 30-65 (USPSTF 2024 preferred; primary HPV testing every 5 years).
2. p16/Ki-67 dual stain is the most clinically validated triage biomarker for HPV-positive women, now with formal ASCCP 2024 recommendations. It reduces unnecessary colposcopies while maintaining sensitivity.
3. Extended HPV genotyping enables precise risk stratification - HPV 16 or 18 warrants immediate colposcopy regardless of other results.
4. DNA methylation markers (especially FAM19A4/miR124-2 and PAX1) show excellent NPV for CIN3+, making them ideal to rule out high-grade disease and avoid overtreatment. Italian 2025 guidelines give conditional GRADE recommendation for combined biomarker + genotyping strategy.
5. ctDNA and liquid biopsy approaches remain investigational for screening but are validated for post-treatment monitoring.
6. The overarching goal is a risk-stratified, individualized approach - not universal colposcopy referral for HPV positivity.

---

• Robbins, Cotran & Kumar Pathologic Basis of Disease (cervical screening and cytology), p. 926
• Berek & Novak's Gynecology (HPV assays table, screening guidelines), p. 846-848
• Clarke MA et al., JLGTD 2024 (ASCCP p16/Ki-67 DS recommendations) - PMID 38446575
• Gori S et al., Br J Cancer 2025 (Italian multisocietal GRADE guideline) - PMID 40931128
• Salta S et al., Clin Epigenetics 2023 (DNA methylation meta-analysis) - PMID 37533074
• Yin M et al., Ann Med 2025 (PAX1 methylation meta-analysis) - PMID 41229153
• Gisca T et al., Diagnostics 2025 (Integrating biomarkers narrative review) - PMID 41464230
• USPSTF Draft Recommendation 2024 - Primary HPV screening

---

Efficacy of Prophylactic HPV Vaccines in Cervical Cancer Prevention

Background and Disease Burden

---

1. Licensed HPV Vaccines - Comparative Overview

---

2. Efficacy Data from Clinical Trials

2.1 Cochrane Network Meta-Analysis 2025 (Highest Level of Evidence)

2.2 Pivotal Trial Data by Vaccine Type

2.3 Efficacy in Older Women (>25 years)

---

3. Age at Vaccination - Critical Efficacy Modifier

---

4. Dosing Schedules - The Single-Dose Revolution

4.1 ESCUDDO Trial - Landmark NEJM 2025 Publication

• Design: 20,330 girls aged 12-16, Costa Rica; 1:1:1:1 randomization (1 or 2 doses of bivalent or nonavalent vaccine)
• Primary endpoint: Persistent HPV 16 or 18 infection, months 12-60
• Non-inferiority margin: 1.25 infections per 100 participants

4.2 Meta-Analysis of Single-Dose Effectiveness (Setiawan et al., PLoS One 2024, PMID 38180991) - 902,368 vaccinated women:

• Single-dose shown to provide immunogenic protection for at least 8 years
• Effectiveness on par with 2 or 3-dose schedules for HPV 16, 18, hrHPV infections, HSIL, CIN2/3
• Further long-term data needed to confirm durability beyond 10 years

4.3 Current Dose Schedules by Guideline Body

---

5. Real-World Population-Level Effectiveness and Herd Protection

5.1 17-Year Post-Introduction Data (DeSieghardt et al., JAMA Pediatrics 2025, PMID 41021257)

5.2 Quadrivalent HPV Vaccine Real-World Systematic Review (Wang et al., Expert Rev Vaccines 2022, PMID 36178094) - 138 publications, 14 years follow-up:

• Countries with high vaccination coverage showed significant reductions in:
  • HPV 6, 11, 16, 18 infection rates
  • Anogenital wart incidence
  • CIN 2/3 rates
  • Invasive cervical cancer incidence (observed in long-running national programs)

5.3 Country-Level Cervical Cancer Impact

---

6. Efficacy Against Pre-Cancerous Lesions (Surrogate Endpoints for Cancer)

---

7. Adjuvant HPV Vaccination Post-Conisation (New Evidence 2025)

• Women who received HPV vaccination around the time of conisation for CIN2/3 showed reduction in:
  • Recurrent CIN 2+ (RR favoring vaccination)
  • Persistent HPV infection post-procedure
• ASCCP (Dec 2025) formally recommends: "Adjuvant HPV vaccination be offered at time of treatment for histologic HSIL (CIN2/3), AIS, and other HPV-related precancers, for previously unvaccinated individuals"

---

8. Immunogenicity and Duration of Protection

Immune Response by Age - Adolescent Advantage

---

9. Special Populations

---

10. Safety Profile

---

11. Current Guideline Recommendations Summary

---

12. WHO 90-70-90 Elimination Strategy

---

13. Limitations and Remaining Evidence Gaps

---

Key Takeaways

1. Prophylactic HPV vaccines have near-perfect efficacy (92-100%) against vaccine-type HPV-associated CIN2+ in HPV-naive adolescents, representing the strongest cancer prevention tool available for any malignancy.
2. Vaccination at ages 9-14 years yields the highest effectiveness (74-93%) and antibody titers, with clear declining benefit as age increases.
3. The ESCUDDO trial (NEJM Dec 2025) definitively established that one dose is non-inferior to two doses for both bivalent and nonavalent vaccines in girls 12-16 years, with ≥97% effectiveness - the most impactful recent development in HPV vaccine strategy.
4. 17 years of real-world US data (JAMA Pediatrics 2025) show up to 98.4% reduction in vaccine-type HPV in vaccinated women, with substantial herd protection (71-76% reduction in unvaccinated women for 2v and 4v types).
5. ASCCP (Dec 2025) now recommends adjuvant HPV vaccination at the time of HSIL/CIN treatment for previously unvaccinated individuals - a new evidence-based indication.
6. WHO's single-dose recommendation (2022-present), now validated by ESCUDDO, has the potential to dramatically expand coverage in LMICs and move toward the WHO 90-70-90 elimination targets.

---

• Bergman H et al., Cochrane NMA 2025 - HPV vaccination for cervical cancer and other HPV diseases (PMID 41276263)
• Kreimer AR et al., NEJM 2025 - ESCUDDO trial: Noninferiority of 1 dose to 2 doses (PMID 41337735)
• Harper DM et al., Hum Vaccin Immunother 2025 - Systematic review of HPV vaccine impact (PMID 40485552)
• DeSieghardt A et al., JAMA Pediatrics 2025 - Population-level effectiveness, 17 years (PMID 41021257)
• Ellingson MK et al., Hum Vaccin Immunother 2023 - Effectiveness by age at vaccination (PMID 37529935)
• Setiawan D et al., PLoS One 2024 - Single-dose meta-analysis, 902,368 women (PMID 38180991)
• Kapp P et al., Cochrane 2025 - HPV vaccination in women with conisation (PMID 40919695)
• ASCCP Statement on HPV Vaccination, Dec 2025
• WHO Cervical Cancer Fact Sheet 2025